The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Christophe De Block studied medicine at the University of Antwerp, Antwerp, Belgium and graduated magna cum laude. He is Head of the Department of Endocrinology-Diabetology & Metabolism at Antwerp University Hospital, Full Professor at the University of Antwerp, and Former President of the Diabetes Liga Belgium.
Prof. De Block’s main clinical and research interests are related to prediction and prevention of type 1 diabetes, autoimmune polyendocrine syndromes, and new treatment options for diabetes, including incretin-based therapies. His latest field of interest focusses on the application of continuous glucose monitoring, functional insulin therapy, and sensor-augmented pump therapy.
Prof. De Block has received several scientific awards, including the Award of the Royal Academy of Medicine of Belgium for experimental investigations on autoimmune diseases, the Young Investigator’s Award of the Belgian Endocrine Society in 2005, and the Novo Nordisk Award for Diabetes 2015–2016. He has published more than 150 papers in international medical journals.
Prof. De Block is a member of the European Association for the Study of Diabetes, the American Diabetes Association, the Endocrine Society, the Belgian Diabetes Registry, and the Belgian Endocrine Society.
Richard M. Bergenstal
International Diabetes Center and Department of Medicine, University of Minnesota, Minneapolis, MN, USA
Richard M. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center at HealthPartners Institute, Minneapolis, MN, USA. He is Clinical Professor in the Department of Medicine at the University of Minnesota, Minneapolis and served as President, Science & Medicine of the American Diabetes Association (ADA) in 2010. In 2007, Prof. Bergenstal was named the ADA’s Outstanding Physician-Clinician of the Year and in 2010 was awarded the Banting Medal for Service. He received his MD and endocrine training from the University of Chicago, Chicago, IL, USA, where he was an Assistant Professor of Medicine before joining the International Diabetes Center in 1983.
His clinical research has focused on glucose control and diabetes complications and advanced technology, including continuous glucose monitoring and automated insulin delivery systems, and he has served as a Principal Investigator of five National Institutes of Health trials.
Prof. Bergenstal’s clinical efforts are directed towards improving systems of care for patients with diabetes by translating new research findings into practice. He teaches on the importance of patient‐centred team care, has been listed in Best Doctors in America since it began in 1992, and has published more than 300 peer-reviewed scientific articles.
Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
Julia Mader is Associate Professor of Medicine at the Division of Endocrinology and Diabetology at the Medical University of Graz, Graz, Austria and is Deputy Head of the Diabetes Outpatient Clinic. She received her medical degree at the Medical University of Graz, where she also trained in Internal Medicine, and Endocrinology and Diabetology. From 2016 to 2017, Prof. Mader was Visiting Professor at the Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism at the University Hospital of Bern, Bern, Switzerland. She leads the Diabetes Technology Research Unit at the Medical University of Graz.
Prof. Mader’s research is focused on diabetes technology with an emphasis on insulin pumps, continuous glucose monitoring, the artificial pancreas and decision support systems. She has published more than 100 peer-reviewed scientific papers and serves as Associate Editor for Frontiers in Clinical Diabetes and Healthcare. Prof. Mader has received several awards in the field of diabetes technology, including the Langerhans award from the Austrian Diabetes Association in 2021. She is a member of several European associations and societies and is a management board member of the Austrian Diabetes Society, within which she heads the Diabetes Education Committee and is a member of the Diabetes Technology Committee. She has authored and co-authored several national guidelines in the field.